Role of cytochrome P450 metabolites of arachidonic acid in regulation of corporal smooth muscle tone in diabetic and older rats

Vascular Pharmacology

Volumn 47, Issue 5-6, 2007, Pages 281-287

  Yousif, Mariam H M ^a   Benter, Ibrahim F ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

20 HETE; Diabetes; Epoxyeicosatrienoic acid; Erectile dysfunction

Indexed keywords

1 CYCLOHEXYL 3 DODECYLUREA; 11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 20 HYDROXYICOSATETRAENOIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ARACHIDONIC ACID; CALCIUM ACTIVATED POTASSIUM CHANNEL; CARBACHOL; CYCLIC GMP; CYTOCHROME P450; EPOXIDE HYDROLASE; FORMAMIDINE; GLIBENCLAMIDE; GUANYLATE CYCLASE; HET 0016; IBERIOTOXIN; ICOSATRIENOIC ACID; N HYDROXY N (4 BUTYL 2 METHYLPHENYL)FORMAMIDINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PHENYLEPHRINE; STREPTOZOCIN; UNCLASSIFIED DRUG;

AGING; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DIABETES MELLITUS; DOSE RESPONSE; ENZYME INACTIVATION; ERECTILE DYSFUNCTION; MALE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; SMOOTH MUSCLE TONE;

8,11,14-EICOSATRIENOIC ACID; AGING; ANIMALS; ARACHIDONIC ACID; CYTOCHROME P-450 ENZYME SYSTEM; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXYEICOSATETRAENOIC ACIDS; KATP CHANNELS; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MALE; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; PENIS; RATS; RATS, WISTAR;

EID: 35548938948     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2007.08.002     Document Type: Article

References (30)

1. Angulo J., Cuevas P., Fernandez A., Gabancho S., Allona A., Martin-Morales A., Moncada I., Videla S., and Saenz de Tejada I. Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF. Biochem. Biophys. Res. Commun. 312 (2003) 1202-1208
2. Angulo J., Cuevas P., Fernandez A., Gabancho S., Videla S., and Saenz de Tejada I. Calcium dobesilate potentiates endothelium-derived hyperpolarizing factor-mediated relaxation of human penile resistance arteries. Br. J. Pharmacol. 139 (2003) 854-862
3. Benter I.F., Yousif M.H., Canatan H., and Akhtar S. Inhibition of Ca2+/calmodulin-dependent protein kinase II, RAS-GTPase and 20-hydroxyeicosatetraenoic acid attenuates the development of diabetes-induced vascular dysfunction in the rat carotid artery. Pharmacol. Res. 52 (2005) 252-257
4. Benter I.F., Francis I., Cojocel C., Juggi J.S., Yousif M.H.M., and Canatan H. Contribution of cytochrome P450 metabolites of Arachidonic acid to hypertension and end-organ damage in spontaneously hypertensive rats with l-NAME. Pharmacol. Res. 25 (2005) 143-154
5. Bivalacqua T.J., Usta M.F., Champion H.C., Adams D., Namara D.B., Abdel-Mageed A.B., Kadowitz P.J., and Hellstrom W.J. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J. Urol. 169 (2003) 1911-1917
6. Campbell W.B., and Falck J.R. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension 49 (2007) 590-596
7. Cartledge J.J., Eardley I., and Morrison J.F. Nitric oxide-mediated corpus cavernosal smooth muscle relaxation is impaired in ageing and diabetes. BJU Int. 87 (2001) 394-401
8. Christ G.J., Stone B., and Melman A. Age-dependent alterations in the efficacy of phenylephrine-induced contractions in vascular smooth muscle isolated from the corpus cavernosum of impotent men. Can. J. Physiol. Pharmacol. 69 (1991) 909-913
9. Coats P., Johnston F., MacDonald J., McMurray J., and Hillier C. Endothelium-derived hyperpolarizing factor: identification and mechanisms of action in human subcutaneous resistance arteries. Circulation 103 (2001) 1702-1708
10. Davis B.B., Thompson D.A., Howard L.L., Morisseau C., Hammock B.D., and Weiss R.H. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2222-2227
11. Fang X., Weintraub N.L., McCaw R.B., Hu S., Harmon S.D., Rice J.B., Hammock B.D., and Spector A.A. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am. J. Physiol., Heart Circ. Physiol. 287 (2004) H2412-H2420
12. Goldstraw M.A., Kirby M.G., Bhardwa J., and Kirby R.S. Diabetes and the urologist: a growing problem. BJU Int. 99 (2007) 513-517
13. Halcox J.P., Narayanan S., Cramer-Joyce L., Mincemoyer R., and Quyyumi A.A. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am. J. Physiol., Heart Circ. Physiol. 280 (2001) H2470-H2477
14. Imig J.D., Zhao X., Capdevila J.H., Morisseau C., and Hammock B.D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39 (2002) 690-694
15. Inceoglu B., Schmelzer K.R., Morisseau C., Jinks S.L., and Hammock B.D. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat. 82 (2007) 42-49
16. Jin L., Foss C.E., Zhao X., Mills T.M., Wang M.H., McCluskey L.P., Yaddanapud G.S., Falck J.R., Imig J.D., and Webb R.C. Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. FASEB J. 20 (2006) 539-541
17. Kim I.H., Morisseau C., Watanabe T., and Hammock B.D. Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J. Med. Chem. 47 (2004) 2110-2122
18. Larsen B.T., Miura H., Hatoum O.A., Campbell W.B., Hammock B.D., Zeldin D.C., Falck J.R., and Gutterman D.D. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am. J. Physiol., Heart Circ. Physiol. 290 (2006) H491-H499
19. Lee S.W., Wang H.Z., and Christ G.J. Characterization of ATP-sensitive potassium channels in human corporal smooth muscle cells. Int. J. Impot. Res. 11 (1999) 179-188
20. Morrison J.F., Pallot D.J., Sheen R., Dhanasekaran S., and Mensah-Brown E.P. The effects of age and streptozotocin diabetes on the sympathetic innervation in the rat penis. Mol. Cell. Biochem. 295 (2007) 53-58
21. Miyata N., Taniguchi K., Seki T., Ishimoto T., Sato-Watanabe M., Yasuda Y., Doi M., Kametani S., Tomishima Y., Ueki T., Sato M., and Kameo K. HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br. J. Pharmacol. 133 (2001) 325-329
22. Musicki B., and Burnett A.L. Endothelial dysfunction in diabetic erectile dysfunction. Int. J. Impot. Res. 19 (2006) 129-138
23. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., Zeldin D.C., and Liao J.K. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 (1999) 1276-1279
24. Priviero F.B., Leite R., Webb R.C., and Teixeira C.E. Neurophysiological basis of penile erection. Acta Pharmacol. Sin. 28 (2007) 751-755
25. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82 (2002) 131-185
26. Schmelzer K.R., Kubala L., Newman J.W., Kim I.H., Eiserich J.P., and Hammock B.D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9772-9777
27. Seki T., Wang M.H., Miyata N., and Laniado-Schwartzman M. Cytochrome P450 4A isoform inhibitory profile of N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine (HET0016), a selective inhibitor of 20-HETE synthesis. Biol. Pharm. Bull. 28 (2005) 1651-1654
28. Shimojo N., Ishizaki T., Imaoka S., Funae Y., Fujii S., and Okuda K. Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozotocin-induced diabetes. Biochem. Pharmacol. 46 (1993) 621-627
29. Yu Z., Xu F., Huse L.M., Morisseau C., Draper A.J., Newman J.W., Parker C., Graham L., Engler M.M., Hammock B.D., Zeldin D.C., and Kroetz D.L. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 87 (2000) 992-998
30. Zhao X., Yamamoto T., Newman J.W., Kim I.H., Watanabe T., Hammock B.D., Stewart J., Pollock J.S., Pollock D.M., and Imig J.D. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J. Am. Soc. Nephrol. 15 (2004) 12442-12445